Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > What did we learn here?

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Sep 12, 2022 8:52am

155 Views

Post# 34956096

RE:RE:What did we learn here?

Yeah good point, maybe they can share this with the docs at the sites.

I think it will matter to potential partners once they have more efficacy data.

It probably shouldn't matter all that much to investors atm given they should be focused on what happens in patient but if eventually they get exciting efficacy data then it could.

I think they have to keep doing this type of work even though it's patients that really matter atm.